Journal article
Modulation of the function of human MDR1 P-glycoprotein by the antimalarial drug mefloquine
CD Riffkin, R Chung, DM Wall, JR Zalcberg, AF Cowman, M Foley, L Tilley
Biochemical Pharmacology | PERGAMON-ELSEVIER SCIENCE LTD | Published : 1996
Abstract
MDRI P-glycoprotein in membranes of human tumor cells of the CEM/VBL100 line was selectively labelled using photoreactive analogs of verapamil, N-(p-azido-3-[125I]salicyl)amino-verapamil ([125I]ASA-V) and prazosin, 2-[4-(4-azido-3-[125I]iodobenzoyl)piperazin-1-yl]4-amino-6,7-dimeth oxyquinazoline ([125I]ASA-P). Mefloquine, a quinolinemethanol antimalarial drug, was shown to inhibit the labelling of P-glycoprotein with an efficiency similar to that for verapamil, a known chemosensitizer. By contrast, chloroquine competed poorly for the binding site on P-glycoprotein. Mefloquine also inhibited the functional activity of P-glycoprotein. It decreased the rates of extrusion of [5H]vinblastine and..
View full abstract